Last reviewed · How we verify

NCT05784623: DIGICOG-start

Interest and Feasibility of the DIGItracking Technique for the Early Diagnosis of COGnitive Disorders

Completed Last updated 27 March 2023
What this trial tests

trial testing User experience in Aging in 135 participants. Completed in 30 April 2022.

Timeline
15 September 2021
Primary endpoint
30 April 2022
30 April 2022

Quick facts

Lead sponsorUniversity Hospital, Angers
StatusCompleted
Study typeOBSERVATIONAL
Enrollment135
Start date15 September 2021
Primary completion30 April 2022
Estimated completion30 April 2022
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Angers

Who can join

75 and older, any sex, with Aging. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main objective is to assess the usability of a novel tool of neurocognitive disorders detection, called the Digitracking, by the elderly population. The Digitracking technique is based on the eye tracking concept to assess cognitive decline (Lio et al. 2019). Instead of capturing eye movements, the new device captures the finger trajectory while exploring a blurred picture on a tablet. The usability of such a technology is assessed through objective and subjective metrics, such as the user experience.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of User experience

Trials testing the same drug.

Other recruiting trials for Aging

Currently open trials in the same condition.

Other University Hospital, Angers trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05784623.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing